CLINICAL EVALUATION OF CHITRAKA HARITAKI AND LAVANGADI VATI IN THE MANAGEMENT OF KAPHAJA KASA (STABLE CHRONIC BRONCHITIS)

Central Council for Research in Ayurvedic Sciences0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Patients of either sex aged between 18 to 65 years.
•2.Patients suffering from Stable Chronic Bronchitis. (Chronic Bronchitis is defined as a cough that occurs every day with sputum production that lasts for at least three months, two years in a row).
•3.Patients having FEV1 > 80%.
•4.Patient willing and able to participate in the study for 16 weeks.

•1.Any other pulmonary diagnosis like Emphysema, Cor pulmonale, Cyanosis, Pneumonia, Asthma, Cystic fibrosis, Tuberculosis, Lung cancer etc.
•2.Patients with uncontrolled Diabetes Mellitus (Blood Sugar Fasting > 250 mg/dl)
•3.Patients with poorly controlled Hypertension ( >=160 / 100 mmHg).
•4.Patients on prolonged ( > 6 weeks) medication with corticosteroids, bronchodilators, Mast cell stabilizers, antidepressants, anticholinergics, etc. or any other drugs that may have an influence on the outcome of the study.
•5.Patients suffering from major systemic illness necessitating long term drug treatment (Rheumatoid arthritis, Tuberculosis, Psycho-Neuro-Endocrinal disorders etc).
•6.Patients who have a past history of Atrial Fibrillation, Acute Coronary Syndrome, Myocardial Infarction, Stroke or Severe Arrhythmia in the last 6 months.
•7.Symptomatic patients with clinical evidence of Heart failure.
•8.Patients with concurrent serious hepatic disorder (defined as Aspartate Amino Transferase (AST) and / or Alanine Amino Transferase (ALT), Total Bilirubin, Alkaline Phosphatase (ALP) > 2 times upper normal limit) or Renal Disorders (defined as S. Creatinine >1.2mg/dL).
•9.Alcoholics and/or drug abusers.
•10.Patients who have completed participation in any other clinical trial during the past six months.
•11.Any other condition which the Investigator thinks may jeopardize the study.

发起方